X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Two companies will start their collaboration with a focus on developing in vivo gene-editing therapies for liver-targeted diseases. This agreement strengthens Bayer’s new cell and gene therapy platform.
Lead Product(s): In Vivo Gene Therapy
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: $1,040.0 million Upfront Cash: $40.0 million
Deal Type: Collaboration January 10, 2022
Details:
The combination of Mammoth’s unique technology with Vertex’s unmatched experience in serious disease research and development will only accelerate programs with the goal of reaching patients with high unmet medical need.
Lead Product(s): In-vivo Gene-editing Therapies
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $691.0 million Upfront Cash: $41.0 million
Deal Type: Collaboration October 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
